TIHANA LENAC ROVIŠ, PHD

Curriculum Vitae

Office Address: Center for Proteomics, Faculty of Medicine, University of Rijeka
B. Branchetta 20, 51000 Rijeka, Croatia
Date of birth: 25.11.1978
Nationality: Croat
URL for web site: https://capri.com.hr/about-tihana-lenac

Tihana Lenac Roviš - Academic Profile

Tihana Lenac Roviš holds a PhD in Biomedicine and is a tenured Full Professor at the University of Rijeka, Faculty of Medicine. Her research focuses on tumor and herpesviral immunobiology, with expertise in protein biology, confocal microscopy, biochemical analyses, and monoclonal antibody development. She leads the Antibody Core Facility, operating under ISO 9001 standards.

She has participated in 15+ competitive projects (including FP7 and H2020) and has served as principal investigator on 10 nationally funded projects. She has contributed to teaching in more than 10 courses and coordinated 9 of them.

She has authored 50+ peer-reviewed publications, accumulating 2834 citations and an h-index of 26 (Google Scholar, January 2026). https://scholar.google.com/citations?authuser=1&user=NBeEi9EAAAAJ.

Her work includes publications in Science and Nature as co-author, and in Journal of Experimental Medicine and Nature Communications as first or corresponding author. https://orcid.org/0000-0002-3299-1334.

Her granted patents include tumor immunotherapy (WO2020144697, 2020; WO2022172267, 2022; Nectin Therapeutics, SME, Jerusalem, Israel) and viral immunotherapy (WO2022268527; Universitätsklinikum Freiburg, Germany).

Top 5 publications (first or corresponding author)

1. Karner D, et al., Lenac Roviš T (corresponding). Prion protein alters viral control and enhances pathology after perinatal CMV infection. **Nature Communications**, 2024. IF 15.7. DOI: 10.1038/s41467-024-51931-4
2. Pietri GP, et al., Lenac Roviš T (corresponding) Antigenic determinants driving serogroup-specific antibody responses to Neisseria meningitidis. **Carbohydrate Polymers**, 2024. IF 12.5 DOI: 10.1016/j.carbpol.2024.122349
3. Stražić Geljić I, et al., Lenac Roviš T (corresponding) CMV protein m154 perturbs AP-1–mediated immune evasion. **eLife**, 2020. IF 7.5 DOI: 10.7554/eLife.50803
4. Lenac Roviš T, et al. DNAM-1-dependent control of CMV infection by monocytes and NK cells**. Journal of Experimental Medicine**, 2016. IF 11.2 DOI: 10.1084/jem.20151899
5. Lenac T, et al. Herpesviral Fc receptor down-regulates NKG2D ligands. **Journal of Experimental Medicine**, 2006. IF 14.6

Selected 5 publications for the symposium "Oncolytic virotherapy in modern cancer treatment – from research to clinical application" (co-author):

1. Biniaris-Georgallis SI, et al., Lenac Roviš T, et al. Amplification of autoimmune organ damage by NKp46-activated ILC1. **Nature**, 2024. DOI: 10.1038/s41586-024-07907-x
2. Worboys JD, et al., Roviš TL, et al. TIGIT inhibits T-cell activation via ligation-induced nanoclusters independent of CD226. **Nature Communications**, 2023. DOI: 10.1038/s41467-023-40755-3
3. Reches A, et al., Lenac T, et al. Nectin-4 is a novel TIGIT ligand linking checkpoint inhibition and tumor specificity. Journal for **ImmunoTherapy of Cancer**, 2020. DOI: 10.1136/jitc-2019-000266
4. Kučan Brlić P, Lenac Roviš T, et al. Targeting PVR (CD155) and its receptors in anti-tumor therapy. **Cellular & Molecular Immunology**, 2019. DOI: 10.1038/s41423-018-0168-y
5. Deng W, et al., Roviš TL, et al. A shed NKG2D ligand promotes NK-cell activation and tumor rejection. **Science**, 2015. DOI: 10.1126/science.1258867